ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,928.84
0.20%
US Tech 100
20,085.20
-0.21%
Dow Jones
43,763.73
0.82%
Brent Oil
73.42
0.80%
Bitcoin
97,131.81
2.94%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Rigel Pharmaceuticals Inc (RIGL) Quote

Rigel Pharmaceuticals Inc

Rigel Pharmaceuticals Inc (RIGL)

NASDAQ
25.01
0.70
( 2.88% )
Updated: 11:47:04
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
25.01
Bid
24.80
Ask
25.00
Volume
63,185
23.74 Day's Range 25.25
7.4843 52 Week Range 29.82
Market Cap
440.552M
Previous Close
24.31
Open
24.35
Last Trade
1
@
24.9657
Last Trade Time
11:47:48
Financial Volume
$ 1,529,514
VWAP
24.2069
Average Volume (3m)
202,813
Shares Outstanding
17,615,040
Dividend Yield
-
PE Ratio
-16.97
Earnings Per Share (EPS)
-1.42
Revenue
116.88M
Net Profit
-25.09M

About Rigel Pharmaceuticals Inc

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For mor... Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit https://www.rigel.com/. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.rigel.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Rigel Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker RIGL. The last closing price for Rigel Pharmaceuticals was $24.31. Over the last year, Rigel Pharmaceuticals shares have traded in a share price range of $ 7.4843 to $ 29.82.

Rigel Pharmaceuticals currently has 17,615,040 shares outstanding. The market capitalization of Rigel Pharmaceuticals is $428.22 million. Rigel Pharmaceuticals has a price to earnings ratio (PE ratio) of -16.97.

Ask ADVFN Intelligence (AI)

RIGL Latest News

More News

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

November 14 2024
Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

November 14 2024
Edgar (US Regulatory)

Rigel to Present at the Jefferies London Healthcare Conference

Rigel to Present at the Jefferies London Healthcare Conference PR Newswire SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 /PRNewswire/ -- Rigel...

November 12 2024
PR Newswire (US)

Form 8-K - Current report

November 07 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

November 07 2024
Edgar (US Regulatory)

Rigel Reports Third Quarter 2024 Financial Results and Provides Business Update

Rigel Reports Third Quarter 2024 Financial Results and Provides Business Update PR Newswire SOUTH SAN FRANCISCO, Calif., Nov. 7, 2024 Third quarter total revenue of $55.3 million, which includes...

November 07 2024
PR Newswire (US)

Rigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition

Rigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition PR Newswire SOUTH SAN FRANCISCO, Calif., Nov. 5, 2024 -    Initial data from the...

November 05 2024
PR Newswire (US)

Rigel Announces Conference Call and Webcast to Report Third Quarter 2024 Financial Results and Business Update

Rigel Announces Conference Call and Webcast to Report Third Quarter 2024 Financial Results and Business Update PR Newswire SOUTH SAN FRANCISCO, Calif., Oct. 31, 2024 SOUTH SAN FRANCISCO, Calif...

October 31 2024
PR Newswire (US)

Rigel Pharmaceuticals Issues Dear Healthcare Provider Letter for GAVRETO® (pralsetinib)

Rigel Pharmaceuticals Issues Dear Healthcare Provider Letter for GAVRETO® (pralsetinib) PR Newswire SOUTH SAN FRANCISCO, Calif., Oct. 24, 2024 SOUTH SAN FRANCISCO, Calif., Oct. 24, 2024...

October 24 2024
PR Newswire (US)

Optime Care Expands Partnership with Rigel Pharmaceuticals to Include Commercial Distribution for TAVALISSE®

ST. LOUIS, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Optime Care, a nationally recognized specialty pharmacy and an AscellaHealth Company, today announces an expanded arrangement with Rigel...

October 16 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-2.79-10.03597122327.829.1622.327527030924.6994986CS
410.3470.483980913414.6729.8213.570528981422.49420599CS
1211.9491.354246365713.0729.8212.6620281318.80896297CS
2615.41160.5208333339.629.827.484352372710.93079904CS
5215.81171.8478260879.229.827.484390717712.02111825CS
156-5.39-17.730263157930.435.156.4221310814.0695105CS
2601.415.9745762711923.6556.4248126722.87521877CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
WORXSCWorx Corporation
$ 2.07
(111.22%)
110.56M
CRNCCerence Inc
$ 4.675
(65.78%)
35.57M
QUBTQuantum Computing Inc
$ 5.095
(38.45%)
92.52M
SPAISafe Pro Group Inc
$ 4.4123
(37.88%)
37.01M
IBGInnovation Beverage Group Limited
$ 1.06
(33.97%)
9.6M
GLXGGalaxy Payroll Group Ltd
$ 1.51
(-61.38%)
1.01M
PYXSPyxis Oncology Inc
$ 2.10
(-45.03%)
10.14M
KURAKura Oncology Inc
$ 9.92
(-37.65%)
8.27M
BLRXBioLineRx Ltd
$ 0.355
(-34.89%)
6.39M
TMTCTMT Acquisition Corporation
$ 4.52
(-29.81%)
18.84k
CDTConduit Pharmaceuticals Inc
$ 0.112951
(22.37%)
499.7M
NVDANVIDIA Corporation
$ 144.855
(-0.71%)
212.11M
AKTSAkoustis Technologies Inc
$ 0.0985
(13.09%)
185.68M
ELABElevai Labs Inc
$ 0.0201
(-6.07%)
175.91M
WORXSCWorx Corporation
$ 2.07
(111.22%)
110.56M

RIGL Discussion

View Posts
dcaf7 dcaf7 7 months ago
Titles of olutasidenib presentations at ASCO:
1. Safety and efficacy of olutasidenib treatment in elderly patients with relapsed/refractory mIDH1 acute myeloid leukemia.
2. Patients with relapsed/refractory mIDH1 AML who proceeded to transplant after olutasidenib treatment.
3. Olutasidenib for mutated IDH1 acute myeloid leukemia: Final five-year results from the phase 2 pivotal cohort.
👍️0
Monksdream Monksdream 7 months ago
RIGL under $2
👍️0
Monksdream Monksdream 8 months ago
RIGL under $2
👍️0
dcaf7 dcaf7 8 months ago
Just published, "Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML)". The results of this phase 2 study support data from registrational cohort demonstrating that Olutasidenib works well in patients previously treated with venetoclax.
https://pubmed.ncbi.nlm.nih.gov/38538632/
👍️0
dcaf7 dcaf7 8 months ago
Good read on Olutasidenib
https://journals.lww.com/oncology-times/fulltext/2024/03000/olutasidenib_as_a_breakthrough_for_r_r_midh1_aml.25.aspx
Important further research: 1) studying whether olutasidenib can eliminate the stem cell fraction within each patient's IDH1-mutant AML; 2) characterization of synthetic lethality involving olutasidenib in IDH1-mutant AML.
👍️0
dcaf7 dcaf7 9 months ago
Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO®
FEBRUARY 22, 2024 7:50AM EST
GAVRETO® (pralsetinib) is an FDA approved targeted therapy for the treatment of RET fusion-positive metastatic non-small cell lung cancer and advanced or metastatic thyroid cancer
Acquisition of established U.S. marketed product further expands Rigel's portfolio and leverages Rigel's existing infrastructure in both the institutional and community settings
GAVRETO generated ~$28M in U.S. net product sales in 2023
👍️0
bme bme 1 year ago
Rigl should be VTGN (Today) one day.
👍️0
bme bme 1 year ago
Yeah. Should be good Q.
👍️0
TucsonPhil TucsonPhil 1 year ago
Hopefully, the inducement grants are being used to hire qualified talent, rather than pad the wallets of friends and relatives.
👍️0
bme bme 1 year ago
Better be good.
👍️0
bme bme 1 year ago
Ugly.
👍️0
The Night Stalker The Night Stalker 1 year ago
nice
👍️0
The Night Stalker The Night Stalker 1 year ago
nice
👍️0
The Night Stalker The Night Stalker 1 year ago
base
👍️0
bme bme 1 year ago
What a shoot! Amazing.
👍️0
bme bme 1 year ago
The next quarter fin should include the rev for TAVALISSE. "In April, Rigel's partner Kissei announced the launch of TAVALISSE in Japan for the treatment of chronic ITP."
1. What else should we expect as for the rev?
2. Result of phase 3 of Fostamatinib3 COVID 19?
3. Status of Fostamatinib-ACTIV4 COVID 19?
4. Partnered Programs?
👍️0
The Night Stalker The Night Stalker 1 year ago
nice fins
👍️0
The Night Stalker The Night Stalker 1 year ago
gem
👍️0
The Night Stalker The Night Stalker 1 year ago
gem
👍️0
The Night Stalker The Night Stalker 1 year ago
easy
👍️0
bme bme 1 year ago
Nice spike AH today.
👍️0
bme bme 1 year ago
Higher low higher low.... next leg is North.
👍️0
The Night Stalker The Night Stalker 1 year ago
https://www.barchart.com/stocks/quotes/RIGL/technical-chart?plot=BAR&volume=total&data=I:120&density=H120&pricesOn=1&asPctChange=0&logscale=0&im=120&indicators=EXPMA(9);SMA(20);BBANDS(20,2);MACD(12,26,9)&sym=RIGL&grid=1&height=500&studyheight=100
👍️0
The Night Stalker The Night Stalker 1 year ago
https://www.barchart.com/stocks/quotes/RIGL/technical-chart?plot=BAR&volume=total&data=I:120&density=H120&pricesOn=1&asPctChange=0&logscale=0&im=120&indicators=EXPMA(9);SMA(20);BBANDS(20,2);MACD(12,26,9)&sym=RIGL&grid=1&height=500&studyheight=100
👍️0
bme bme 1 year ago
acting wild atm, but still healthy.
👍️0
The Night Stalker The Night Stalker 1 year ago
nice
👍️0
bme bme 1 year ago
Nice & Healthy.
👍️0
The Night Stalker The Night Stalker 1 year ago
quite the dip
👍️0
The Night Stalker The Night Stalker 1 year ago
ready
👍️0
The Night Stalker The Night Stalker 1 year ago
ready
👍️0
The Night Stalker The Night Stalker 2 years ago
red to green
👍️0
The Night Stalker The Night Stalker 2 years ago
red to green
👍️0
bme bme 2 years ago
Wonderful!
👍️0
The Night Stalker The Night Stalker 2 years ago
beauty
👍️0
The Night Stalker The Night Stalker 2 years ago
nice
👍️0
bme bme 2 years ago
Expect Q4 filing this week?
👍️0
bme bme 2 years ago
Be seeing that. Lot of 1.95 transactions so far
👍️0
TucsonPhil TucsonPhil 2 years ago
Revenue potential appears good. SP is slowly rising, and looks like it has been in accumulation for the past few weeks.
👍️0
bme bme 2 years ago
SP should be a lot higher since the Q4 revenue is more than double from last year...
👍️0
Welldoctor Welldoctor 2 years ago
Apparently insider buying reported on ST. Take it for what it’s worth.
👍️0
Welldoctor Welldoctor 2 years ago
RIGL news out
👍️0
bme bme 2 years ago
Looks like it will poke thru & bye bye 1 today.
👍️0
doesitreallymatter doesitreallymatter 2 years ago
Just like ABQQ. Right?
👍️0
subslover subslover 2 years ago
You are 1/2 way there!!!!
👍️0
KngmAz KngmAz 2 years ago
Wow - BOOM - we just went over a dollar - next step $10.00 - DON'T MISS OUT!!
👍️0
KngmAz KngmAz 2 years ago
This is a $10.00 per share stock in the very near future - EASILY!!
👍️0
Alaska40 Alaska40 2 years ago
I just bought in. Seems like a good run could come in the near future.
👍️0
subslover subslover 2 years ago
Consolidating nicely on Continuation from last week!
👍️0
bcapps66 bcapps66 2 years ago
LOL!
👍️0
THEMASTERS_SON THEMASTERS_SON 2 years ago
GIVE ME MY $2DOLLAS…YA BUM
👍️0

Your Recent History

NASDAQ
RIGL
Rigel Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved